Morgan Stanley analyst Stephen Byrd downgrades Array Technologies (NASDAQ:ARRY) from Equal-Weight to Underweight and lowers the price target from $17 to $15.
Piper Sandler Maintains Overweight on Fulcrum Therapeutics, Raises Price Target to $21
Piper Sandler analyst Edward Tenthoff maintains Fulcrum Therapeutics (NASDAQ:FULC) with a Overweight and raises the price target from $18 to $21.